Vinblastine: vinca alkaloid mitotic inhibitor in oncology
Vinblastine is a mitotic inhibitor from the class of vinca alkaloids, originally isolated from the Madagascar periwinkle (Catharanthus roseus). Introduced in 1958, vinblastine was, alongside vincristine, one of the first drugs to bring the concept of targeted mitotic inhibition into oncology. Compared with vincristine, vinblastine has more pronounced myelotoxic effects and less neurotoxicity, which shapes its indications.
Today vinblastine is part of several established chemotherapy regimens, particularly in Hodgkin lymphoma, testicular cancer and some sarcomas. The drug is also used in histiocytosis and in some rare malignancies.
Mechanism of action
Vinblastine binds to tubulin subunits and prevents their polymerisation into microtubules. Microtubules are essential components of the spindle apparatus, which moves chromosomes to the daughter cells in mitosis. If the spindle cannot be properly assembled, cell division arrests in metaphase and programmed cell death (apoptosis) is triggered.
In contrast to paclitaxel, which stabilises microtubules, vinblastine destabilises them. Both pathways arrest mitosis, but with different toxicity profiles. While vincristine is mainly neurotoxic, vinblastine is dominated by bone marrow toxicity with neutropenia and thrombocytopenia.
Vinblastine is metabolised hepatically via CYP3A4 and eliminated biliary. The half life is about 24 hours.
Indications
- Hodgkin lymphoma: classical component of the ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine)
- Testicular cancer: in some alternative regimens such as VeIP (vinblastine, ifosfamide, cisplatin) for relapse
- Langerhans cell histiocytosis (LCH): standard agent
- Kaposi sarcoma: intralesional or systemic
- Breast cancer (rare today) and bladder cancer: in some historical or special protocols
- Off label: rare soft tissue sarcomas, idiopathic thrombocytopenic purpura in rare cases
Dosing and administration
Standard dose: 6 mg per m² body surface intravenously as bolus or short infusion, every 2 to 4 weeks depending on the protocol. In ABVD classically 6 mg per m² on days 1 and 15 of every 28 day cycle.
Route: exclusively intravenous, never intrathecally (would be fatal, the same safety standards as for vincristine apply). Mini bag administration (50 ml of 0.9 % saline) is the standard to prevent inadvertent intrathecal use.
Vesicant: vinblastine is tissue necrotising on extravasation. If extravasation is suspected stop the infusion immediately, aspirate, give hyaluronidase as antidote, apply heat.
Adverse effects
Very common: myelosuppression (especially neutropenia, thrombocytopenia), nausea, vomiting, mucositis, alopecia, fatigue, anorexia.
Common: mild peripheral polyneuropathy (less marked than with vincristine), constipation, abdominal pain, raised liver transaminases, rare hyponatraemia from SIADH.
Uncommon: bronchospasm or pneumonitis, especially in combination with mitomycin or with repeated doses; orthostatic hypotension, fever, rash.
Rare and very rare: tumour lysis syndrome, myocardial ischaemia, hepatic changes, ileus, severe irreversible polyneuropathy, infusion related reactions.
Important points:
- Marrow check at least before every cycle, often weekly
- With neutropenia below 1,500 per microlitre pause therapy or reduce dose
- Because of vesicant action always infuse into a securely placed vein
- Sudden dyspnoea, cough or pulmonary symptoms should raise suspicion of pneumonitis
Interactions
- Strong CYP3A4 inhibitors (itraconazole, voriconazole, posaconazole, erythromycin, HIV protease inhibitors): drastically raised levels with dangerous toxicity
- Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort): reduced effectiveness
- Mitomycin: increased pneumonitis risk
- Other myelotoxic substances: additive toxicity
- Live vaccines: contraindicated during and several months after therapy
- Phenytoin: reduced phenytoin levels with seizure risk
Special considerations
Pregnancy: contraindicated, markedly teratogenic. Reliable contraception during therapy and for at least 6 months after for both sexes.
Breastfeeding: contraindicated.
Fertility: vinblastine can impair fertility; counselling on fertility preservation (cryopreservation) before therapy is sensible.
Liver disease: dose reduction needed, since hepatic metabolism dominates.
Bronchospasm risk: caution in combination with mitomycin and in patients with asthma.
Patient communication: vinblastine is part of intensive treatment protocols. Realistic information about tolerance, frequency of infusions and possible adverse event management (antiemetics, growth factors for neutropenia) supports adherence.
Related substances
- Vincristine, sister drug with a different toxicity profile
- Paclitaxel, microtubule stabilising mitotic inhibitor
- Etoposide, topoisomerase 2 inhibitor
- Methotrexate, antimetabolite standard
- Pemetrexed, folate antimetabolite
Frequently asked questions
How does vinblastine differ from vincristine?
Both are vinca alkaloids with the same mechanism. Vincristine is markedly more neurotoxic with polyneuropathy as dose limiting toxicity, but less myelotoxic. Vinblastine is the opposite: more myelotoxic (neutropenia, thrombocytopenia) and less neurotoxic. The choice in a given regimen depends on indication and tolerance profile.
Why must vinblastine never be given intrathecally?
As with vincristine, intrathecal administration causes ascending myelopathy and is regularly fatal. Vinca alkaloids are therefore supplied internationally as a mini bag in 50 ml saline, which practically prevents inadvertent intrathecal use.
What checks are important during therapy?
Before every cycle full blood count with neutrophils and platelets, liver enzymes, creatinine, electrolytes. Imaging if pulmonary symptoms appear. Medical assessment for new neurological symptoms. Regular imaging for response monitoring.
Do I need preventive antiemetics?
Yes, vinblastine causes moderate nausea and vomiting. Antiemetic prophylaxis with 5 HT3 antagonists (ondansetron, granisetron) and where needed steroids is standard. In regimens such as ABVD antiemesis is planned in combination with the other emetogenic agents.
Sources
- EMA European Medicines Agency
- BfArM German Federal Institute for Drugs and Medical Devices
- AWMF oncology guidelines Hodgkin and testicular cancer
- Gelbe Liste vinblastine monograph
Legal notice and disclaimer
The information on this page is provided for general information only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace advice from a qualified physician or pharmacist. Medicines should only be used on prescription or after dispensing by a pharmacist. All information is based on the product information available at the time of writing and on recognised scientific sources; the manufacturer's current product information always prevails. Sanoliste assumes no liability for completeness, timeliness or accuracy of the information presented. In a medical emergency call the European emergency number 112.